BRAF and neoplasm: However, once resistance to BRAF inhibitors develops, the tumor microenvironment reverts to its low immunogenic state, with fewer infiltrating T-cells and NK cells [9,160], more double-negative T-cells [9,161], and restoration of myeloid-derived suppressor cells [162].